Contact

UK Office

Only Medics
33 Blagrave Street
Reading, Berkshire
RG1 1PW, UK

Tel -
+44(0)1189 522799

Email -
info@onlymedics.com

EU Office

Only Medics
11 - 12 Bouverie Street
London
EC4Y 8DP, UK

Tel -
+44(0)2078 221719

Share &
Connect


Keep connected & join the Only Medics Network here.

Only Medics LinkedIn Only Medics Facebook Only Medics Twitter
Clinical Professionals Pinterest Clinical Professionals YouTube Only Medics Google+
Pharmaceutical Jobs Integrated Regulatory Outsourcing Medical Communication Jobs

Medicines and Healthcare products Regulatory Agency has cleared the adjuvanted trivalent influenza vaccine Fluad for use in people aged 65 years or older.

Fluad, which is manufactured by CSL company Seqirus, has been available in Europe since 1997 but has only just been launched in the UK.

According to the Joint Committee on Vaccination and Immunisation (JCVI), adjuvanted trivalent influenza vaccine (aTIV) studies have indicated a “higher vaccine immunogenicity and effectiveness for the adjuvanted vaccine in comparison with non-adjuvanted vaccines”, and could “potentially be used in the [influenza] programme from the 2018/19 season”.

“The burden of influenza in adults aged 65 years and over continues to be a significant and major problem, causing many thousands of hospitalisations and substantial excess mortality every winter,” noted GP and immunisation expert, Dr George Kassianos.

“Older patients have a weaker response to existing conventional non-adjuvanted vaccines. The evidence shows that this new adjuvanted influenza vaccine boosts the immune response in adults aged 65 years and over, and thereby offers greater protection for this specific age group when compared to existing conventional non-adjuvanted influenza vaccines.”

“This adjuvanted vaccine has a well-established safety and tolerability profile through its use in Europe and other parts of the world,” added Pauline MacDonald, an independent consultant nurse specialising in immunisation and former member of the JCVI.

“Its approval in the UK offers a new effective option for healthcare professionals when making decisions about which influenza vaccines might be the most appropriate for their specific patient groups, particularly for those adults aged 65 years and older.”

Source: PharmaTimes

Return to the news archive

Job Search

Advanced job search

Register your C.V.